Good News on the HIV Front

Key Takeaways

• Over 250 HIV vaccine trials; best achieved only 31% immunity
• PrEP reduces sexual HIV transmission by 99%, injection drug use by 74%
• Lenacapavir injectable is 99% effective, administered twice yearly
• Mother‑to‑child HIV infections dropped from 1 in 4 to under 5,000 globally
• Engineered broadly neutralizing antibodies show functional cure potential in trials

Pulse Analysis

Since the first HIV vaccine attempts in the 1990s, scientists have wrestled with a virus that hides behind a dense glycan shield and mutates faster than most pathogens. The envelope’s 95 distinct sugar molecules mask protein targets, while the virus’s sloppy gene duplication creates dozens of subtypes, thwarting traditional protein‑based vaccine designs. Consequently, more than 250 vaccine trials have been launched, yet the most successful candidate only provoked modest immunity in roughly a third of participants. This biological complexity explains why a conventional vaccine remains elusive beyond 2030.

The public health response has instead leaned on antiretroviral therapy and preventive regimens that sidestep the need for a vaccine. Combination treatments transformed HIV/AIDS from a death sentence into a manageable chronic condition, while pre‑exposure prophylaxis (PrEP) cuts sexual transmission risk by 99% and reduces needle‑share infections by 74%. In 2024, Gilead’s long‑acting injectable lenacapavir, offered at cost through partnerships with the Global Fund and PEPFAR, demonstrated 99% efficacy with twice‑yearly dosing, a game‑changer for low‑resource settings and mother‑to‑child transmission.

A parallel frontier is passive immunization using engineered broadly neutralizing antibodies (bnAbs). Early animal studies identified natural antibodies that could neutralize diverse HIV strains, and synthetic copies are now entering human trials. Some participants have maintained viral suppression for months after stopping antiretroviral drugs, hinting at a functional cure—control without lifelong medication. Challenges remain, such as the need for biannual infusions and scalable manufacturing, but the approach promises a new therapeutic class that could reshape HIV treatment guidelines and attract substantial investment as the next decade unfolds.